Arca Biopharma | ABIO - Assets


Arca Biopharma reported $1.14B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Amgen USD 95.64B 3.14B Jun/2026
Arca Biopharma USD 1.14B 634.91M Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
Brainstorm Cell Therapeutics USD 788K 33K Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Capricor Therapeutics USD 368.74M 42.45M Jun/2026
Cipla INR 424.96B 23.32B Mar/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 145.86M 10.71M Mar/2026
CSL USD 37.9B 1.5B Dec/2025
Cytokinetics USD 1.92B 651.07M Jun/2026
Daiichi Sankyo JPY 4.11T 109.16B Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Grifols EUR 23.15B 142.7M Dec/2025
Laboratory Of America USD 18.53B 554.8M Jun/2026
Myriad Genetics USD 638.9M 34.8M Jun/2026
Otsuka Holdings JPY 4.4T 186.7B Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
United Therapeutics USD 7.22B 505.9M Jun/2026